<div id="readability-page-1"><div> (RTTNews) - ProMIS Neurosciences Inc. (PMN), a clinical-stage biotechnology company, reported financial results for the full year 2025 and provided updates for its lead investigational candidate PMN310 developed for the treatment of Alzheimer's disease. The Company Profile ProMIS Neurosciences develops therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The company's proprietary target discovery engine, EpiSelect, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. The key antibody pipeline programs of ProMIS includes, -PMN310, the company's lead product candidate which is a humanized IgG1 monoclonal antibody for the treatment of Alzheimer's disease. -PMN267 is the firm's preclinical candidate antibody designed as a potential therapeutic target for amyotrophic lateral sclerosis and other TDP-43 proteinopathies. -PMN442 is ProMIS' selected antibody for Parkinson's Disease (PD), Dementia with Lewy Bodies and Multiple System Atrophy (MSA) Disease and is in preclinical stage. FY25 Results For 2025, ProMIS incurred a net loss of $39.72 million or $22.61 loss per share compared to a net income of $2.78 million or $2.63 per share in the year ago period. As of December 31,2025, the firm had a cash of $6.1 million and following the private placement for gross proceeds of $75.5 million in February 2026, the resources are expected to fund planned operations through 2027, including completion of the PRECISE-AD Phase 1b trial. Pipeline Update Based on the encouraging results from the Phase 1a trial of PMN310 in healthy volunteers, ProMIS initiated PRECISE-AD, a Phase 1b clinical trial in AD patients. The firm has completed the enrollment of 144 participants, which is oversubscribed from the targeted 128 in PRECISE-AD Phase 1b trial across 3 dosing cohorts. The six-month assessment is expected to be completed in the second quarter of 2026 and blinded interim data is expected in early third quarter 2026. ProMIS anticipates top line results in early 2027, subject to completion of the final patient visit and database lock. According to Grand View Research, the global Alzheimer's therapeutics market size was estimated at $4.05 billion in 2022 and is anticipated to reach $15.19 billion by 2030, growing at a CAGR of 19.99% from 2023 to 2030. PMN has traded between $6.27 and $39.75 in the last year. The stock closed Wednesday's trade at $15.85, down 9.06% For More Such Biotech and Pharmaceutical News, visit rttnews.com. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. </div></div>

ARKG

ProMIS Neurosciences Inc. reported a FY25 net loss of $39.72 million, a significant drop from a net income of $2.78 million in the previous year. The company is developing PMN310, a monoclonal antibody for Alzheimer's treatment, and has initiated the PRECISE-AD Phase 1b trial, enrolling 144 participants. Interim data is expected in early Q3 2026, with top-line results anticipated in early 2027. Following a private placement, ProMIS has $6.1 million in cash, expected to fund operations through 2027. The global Alzheimer's therapeutics market is projected to grow from $4.05 billion in 2022 to $15.19 billion by 2030.

nasdaq

ProMIS Neurosciences

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

VG Health

VanEck Biotech ETF

Minerva Neurosciences

Alto Neuroscience

SPDR S&P Biotech

iShares Biotechnology ETF

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

Invesco Nasdaq Biotechnology ETF

ProMIS Slides To FY25 Net Loss; Expects Interim Data From Phase 1b Trial Of PMN310 In Early Q3 2026